Results from clinical study of BBS-Bioactive Bone Substitutes’ ARTEBONE® paste showed a fusion rate comparable with that of autograft. ARTEBONE paste was used as a bone void filler in the ankle and subtalar joints. Thirty-four subjects were enrolled at five sites in Finland and Poland, with results compared to the literature references on autograft, the gold standard for fusion.
Primary results demonstrated that the fusion rate with ARTEBONE paste is comparable with the fusion rate with autograft, without safety concerns or product related complications. It offers an alternative to the known risks and morbidity associated with autograft and synthetic bone growth factor products.
ARTEBONE comprises a ready-to-use mineral scaffold and bone proteins that promote bone growth in the extremities, scapula and pelvis.
BBS expects to receive approval under the CE Mark and commercial launch in Europe within 12 months.
Results from clinical study of BBS-Bioactive Bone Substitutes' ARTEBONE® paste showed a fusion rate comparable with that of autograft. ARTEBONE paste was used as a bone void filler in the ankle and subtalar joints. Thirty-four subjects were enrolled at five sites in Finland and Poland, with results compared to the literature references on...
Results from clinical study of BBS-Bioactive Bone Substitutes’ ARTEBONE® paste showed a fusion rate comparable with that of autograft. ARTEBONE paste was used as a bone void filler in the ankle and subtalar joints. Thirty-four subjects were enrolled at five sites in Finland and Poland, with results compared to the literature references on autograft, the gold standard for fusion.
Primary results demonstrated that the fusion rate with ARTEBONE paste is comparable with the fusion rate with autograft, without safety concerns or product related complications. It offers an alternative to the known risks and morbidity associated with autograft and synthetic bone growth factor products.
ARTEBONE comprises a ready-to-use mineral scaffold and bone proteins that promote bone growth in the extremities, scapula and pelvis.
BBS expects to receive approval under the CE Mark and commercial launch in Europe within 12 months.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
